UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic virus ICVB-1042 ...

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...

脑胶质瘤是一种极具侵袭性和破坏性的原发性脑肿瘤，常规治疗手段对其效果不佳。患者在接受手术、放化疗等多学科治疗后，中位生存期仅约 15 个月。溶瘤病毒作为一种新兴的治疗方式，能选择性地在癌细胞内复制并杀死癌细胞，同时引发抗肿瘤免疫反应，在脑胶质瘤治疗中展现出一定潜力。例如，溶瘤腺病毒 Delta 24 - RGD 已完成 I 期研究，部分患者实现了长期生存；G207、HSV1716 ...

UroGen Pharma (NASDAQ:URGN) on Thursday announced the acquisition of oncolytic virus ICVB-1042 and related assets from the ...

UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an early-phase oncolytic virus that could work like a turbocharged Bacillus Calmette ...

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

Oncolytic viruses are therapeutic agents used for in situ immunization in cancer immunotherapy. Unfortunately, its efficacy is particularly limited in solid tumors expressing stimulator of interferon ...

(NASDAQ: URGN), a biotech company focused on urothelial and specialty cancers trading at $10.82 per share, has announced the acquisition of a novel oncolytic virus, ICVB-1042, from IconOVir Bio ...

“The acquisition of ICVB-1042, a next-generation investigational oncolytic virus, marks a significant milestone in our plan to develop novel, locally administered therapies for bladder cancer ...

PRINCETON, N.J. - UroGen Pharma Ltd. (NASDAQ: URGN), a biotech company focused on urothelial and specialty cancers trading at $10.82 per share, has announced the acquisition of a novel oncolytic virus ...